

OPEN ACCESS

EDITED AND REVIEWED BY Heather Cunliffe, University of Otago, New Zealand

*CORRESPONDENCE
Rong Na
Image: Name of the company of the company

SPECIALTY SECTION

This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology

RECEIVED 15 February 2023 ACCEPTED 16 March 2023 PURLISHED 22 March 2023

CITATION

Na R and Li Q (2023) Editorial: The roles of genome and epigenome in poorly studied male-specific cancers. *Front. Oncol.* 13:1166320. doi: 10.3389/fonc.2023.1166320

COPYRIGHT

© 2023 Na and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: The roles of genome and epigenome in poorly studied male-specific cancers

Rong Na^{1*} and Qiyuan Li²

¹Department of Surgery, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China, ²National Institute for Data Science in Health and Medicine, School of Medicine, Xiamen University, Xiamen, China

KEYWORDS

cancer, male, prostate cancer, Paget disease, breast cancer

Editorial on the Research Topic:

The roles of genome and epigenome in poorly studied males specific cancers

Male-specific cancers, such as prostate cancer, male breast cancer, testicular cancer, etc., have become one of the major health issues worldwide (1). Except for prostate cancer, most of the other male-specific cancers are less studied compared to their female-specific counterparts (i.e., breast cancer, ovarian cancer). More and more recent reports suggested that male-specific cancers carry characteristic changes in the genome due to sex differences (2–4). We, therefore, initiated this special topic to discuss these under-reported diseases. The topic contains 4 original research articles and 1 review article which have involved different male-specific malignancies, including prostate cancer, male Paget disease, and male breast cancer.

Johnson et al. presented a comprehensive review regarding the genetic contributions to prostate cancer in Men with West African ancestry. As one of the least developed regions in the world, very little evidence could be obtained regarding the disease characteristics. In this review, the authors discussed the potential disparities between West African ancestry and other ancestries (in particular, the general African American population). In addition to the evidence provided by this review, it may also bring more attention from the readers to the healthcare issues in under-represented populations in the world.

Two research articles provided new classifications of prostate cancer using different genetic signatures (Cheng et al., 2021;Yu et al., 2022). One of the studies presented a subgroup of prostate cancer with significant enrichment of genetic variants in metabolism-related genes (Yu et al., 2022). Another study identified a subgroup of prostate cancer with a poorer prognosis which embraces significant expression variations in immune-related

Na and Li 10.3389/fonc.2023.1166320

genes (Cheng et al., 2021). The results provided different angles in understanding the biological mechanisms of prostate cancer.

Penoscrotal extramammary Paget disease is a rare and poorly studied malignancy in men. Though most male Paget diseases are indolent (but commonly recurrent), some cases could have very invasive phenotypes. Rao et al. performed whole exome sequencing in six paired invasive vs. indolent (in situ) penoscrotal extramammary Paget diseases in Chinese male patients and found several potential genes that might contribute to the disease progression. This research article provides important new evidence to prompt further in-depth research into this poorly understood disease.

In sharp contrast to female breast cancer, for which thousands of research articles have been published, male breast cancer has been less studied. Last but not least, a group of physicians and scientists from Italy reported their most recent results on this topic (Valentini et al., 2022). As one of the two studies explored the genomic landscape of male breast cancer to date, this research article would no doubt provide important information for us to better understand the mechanism of carcinogenesis, as well as to provide better disease management with precision medicine approaches. The results from this study also revealed the potential differences between male breast cancer and well-studied female breast cancer, which might raise the research interest in this topic among the readers for further investigation.

In summary, these five articles collected on the current Research Topic not only provide scientific values, but also (and this is more important) draw researchers' attention to these under-represented diseases, known as male-specific cancers.

References

- 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: Cancer J For Clin* (2021) 71:209–49. doi: 10.3322/caac.21660
- 2. Li CH, Haider S, Shiah Y-J, Thai K, Boutros PC. Sex differences in cancer driver genes and biomarkers. Cancer Res (2018) 78:5527–37. doi: 10.1158/0008-5472.CAN-18-0362

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Acknowledgments

We would like to warmly thank the authors, editorial board, and colleagues who kindly served as reviewers. Their professionalism and support are much appreciated.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

- 3. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Boutros PC. Sex differences in oncogenic mutational processes. *Nat Commun* (2020) 11.
- 4. Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. *Nat Rev Cancer* (2021) 21:393–407. doi: 10.1038/s41568-021-00348-y